MTX, as an anti-cancer drug widely used for leukemia and other malignancies, is a structural analogue of folic acid that can inhibit the metabolism of folic acid by competitively inhibiting dihydrofolate reductase, thereby inhibiting the de novo synthesis of purines and pyrimidines [21]. Here, DHFR is linked to leukemia.